Oncology Letters

1792-1074 1792-1082

D.A. Spandidos

10.3892/ol.2026.15688

OL-32-2-15688

Corrigendum

[Corrigendum] Imatinib mesylate and nilotinib decrease synthesis of bone matrix in vitro

Kroschwald

Lysann Michaela

Tauer

Josephine Tabea

Kroschwald

Sonja Ingrid

Suttorp

Meinolf

Wiedenfeld

Anne

Beissert

Stefan

Bauer

Andrea

Rauner

Martina

082026

10062026

32 2

333

2026

This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, reproduction and adaptation in any medium and for any purpose provided that it is properly attributed. For attribution, the original author(s), title, publication source (PeerJ) and either DOI or URL of the article must be cited.

Oncol Lett 18: 2102–2108, 2019; DOI: 10.3892/ol.2019.10518

Following the publication of the above paper, it was drawn to the Editor's attention by a concerned reader that, regarding the experiments showing the synthesis of mineralized bone matrix in the osteoblast-like cell line SaOS-2 in Fig. 1 on p. 2104, the ‘Day 10/Control’ and ‘Day 15/IAM’ data panels were apparently matching, suggesting that the data in this figure had been assembled incorrectly.

The authors have realized that the ‘Day 10/Control’ data panel was inadvertently copied across to show the results of the ‘Day 15/IAM’ experiment. The revised version of Fig. 1, now showing the correct data panel for the ‘Day 15/IAM’ experiment, is shown on the next page. The authors regret the error that were made while compiling the original figure, and are grateful to the editor of Oncology Letters for allowing them the opportunity to publish this Corrigendum. Note that this error did not have a significant impact on the conclusions reported in this study. All the authors agree with the publication of this corrigendum; furthermore, they apologize to the readership for any inconvenience caused.

Figure 1.

Synthesis of mineralized bone matrix in the osteoblastic-like cell line SaOS-2 under treatment with IMA (middle column, 1 µM) and NIL (1 µM, right-hand column) in comparison with untreated control (left-hand column): Hemofix-stained samples at different time points (day 0, 5, 10, 15 or 25) of incubation. Mineralized areas are represented by black areas. Representative pictures are shown (n=3). IMA, imatinib; NIL, nilotinib.

Synthesis of mineralized bone matrix in the osteoblastic-like cell line SaOS-2 under treatment with IMA (middle column, 1 µM) and NIL (1 µM, right-hand column) in comparison...